Cerenome (PSTV) Free Cash Flow (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Free Cash Flow of -$7.1 million for Q1 2026, down 14.27% year-over-year from -$8.2 million in Q1 2025, and down 11.91% quarter-over-quarter from -$6.3 million in Q4 2025.
Cerenome (PSTV) Free Cash Flow (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Free Cash Flow for 17 consecutive years, with -$7.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 14.27% year-over-year to -$7.1 million; the TTM figure through Mar 2026 stood at -$21.7 million (down 76.29% YoY), while the FY2025 annual figure was -$20.8 million, down 94.79% from the prior year.
- Free Cash Flow eased to -$7.1 million in Q1 2026 per PSTV's latest filing, from -$6.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $634000.0 in Q4 2023 and bottomed at -$7.1 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$3.8 million across 5 years, with a median of -$3.7 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow jumped 112.09% — and 2025, when it tumbled 415.96%.
- Plus Therapeutics' Free Cash Flow stood at -$5.2 million in 2022, then surged by 112.09% to $634000.0 in 2023, then sank by 292.74% to -$1.2 million in 2024, then sank by 415.96% to -$6.3 million in 2025, then fell by 11.91% to -$7.1 million in 2026.
- Business Quant data shows PSTV's Free Cash Flow at -$7.1 million in Q1 2026, -$6.3 million in Q4 2025, and -$2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -7.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.06 Mn |
| Mar 31, 2026 | -7.06 Mn |
| Dec 31, 2025 | -6.31 Mn |
| Dec 31, 2025 | -6.31 Mn |
| Sep 30, 2025 | -2.56 Mn |
| Sep 30, 2025 | -2.56 Mn |
| Jun 30, 2025 | -5.81 Mn |
| Jun 30, 2025 | -5.81 Mn |
| Mar 31, 2025 | -6.18 Mn |
| Mar 31, 2025 | -6.18 Mn |
| Dec 31, 2024 | -1.22 Mn |
| Dec 31, 2024 | -1.22 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Sep 30, 2024 | -3.69 Mn |
| Jun 30, 2024 | -1.23 Mn |
| Jun 30, 2024 | -1.23 Mn |
| Mar 31, 2024 | -4.55 Mn |
| Mar 31, 2024 | -4.55 Mn |
| Dec 31, 2023 | 634,000.00 |
| Dec 31, 2023 | 634,000.00 |